Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Av. Menendez Pidal s/n, 14004 Cordoba, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
Nutrients. 2020 Oct 21;12(10):3219. doi: 10.3390/nu12103219.
Several studies indicate that oxidative stress might play a central role in the initiation and maintenance of cardiovascular diseases. It remains unclear whether ceruloplasmin acts as a passive marker of inflammation or as a causal mediator. To better understand the impact of ceruloplasmin blood levels on the risk of cardiovascular disease, and paying special attention to coronary heart disease, we conducted a search on the two most commonly used electronic databases (Medline via PubMed and EMBASE) to analyze current assessment using observational studies in the general adult population. Each study was quality rated using criteria developed by the US Preventive Services Task Force. Most of 18 eligible studies reviewed support a direct relationship between ceruloplasmin elevated levels and incidence of coronary heart disease. Our results highlight the importance of promoting clinical trials that determine the functions of ceruloplasmin as a mediator in the development of coronary heart disease and evaluate whether the treatment of elevated ceruloplasmin levels has a role in the prognosis or prevention of this condition.
几项研究表明,氧化应激可能在心血管疾病的发生和维持中起核心作用。目前尚不清楚铜蓝蛋白是作为炎症的被动标志物还是作为因果中介物发挥作用。为了更好地了解铜蓝蛋白血液水平对心血管疾病风险的影响,并特别关注冠心病,我们在两个最常用的电子数据库(通过 PubMed 进行的 Medline 和 EMBASE)上进行了搜索,以分析使用一般成年人群的观察性研究进行的当前评估。每个研究都使用美国预防服务工作组制定的标准进行质量评级。审查的 18 项合格研究中的大多数都支持铜蓝蛋白升高水平与冠心病发病率之间存在直接关系。我们的研究结果强调了开展临床试验的重要性,这些临床试验将确定铜蓝蛋白作为冠心病发展中介物的功能,并评估升高的铜蓝蛋白水平的治疗是否对这种情况的预后或预防有作用。